Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Tel HaShomer
Clinical trial register · Israel

Clinical Trials in Tel HaShomer, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Israel and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2438 matching records held by the registry are in this view. Synced 28 Oct 2026, 03:18 UTC
2438
Studies in scope
all four open statuses
1243
Recruiting now
open to new participants
461
Lead sponsors
across recruiting studies
Top sites
Jerusalem 848 Haifa 738 Tel Aviv 691 Ramat Gan 653 Petah Tikva 619
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca6 Sheba Medical Center6 Novo Nordisk A/S4 Regeneron Pharmaceuticals3 Celgene3
Site location
Jerusalem848 Haifa738 Tel Aviv691 Ramat Gan653 Petah Tikva619
All 102 locations
Target enrolment
to

Trials with a site in Tel HaShomer

83 of 2438 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Israel
Start
Recruiting
VectivBio AG
Phase 3
124
Haifa, Jerusalem, Kfar Saba, Tel Aviv, Tel HaShomer
2026-08
By invitation
Sheba Medical Center
Phase 1/2
41
Tel HaShomer
2026-07-26
Recruiting
Bayer
Phase 3
117
Holon, Tel HaShomer, Jerusalem, Tel Aviv
2026-06-01
Recruiting
Portable VR-based Chromatic Pupilloperimeter for Diagnosis and Monitoring of Traumatic Brain Injury
NCT07474987Traumatic Brain Injury (TBI) Patients, Healthy Participants, Non-TBI Trauma
Sheba Medical Center
Observational
150
Tel HaShomer
2026-04-01
Not yet open
Sheba Medical Center
Phase 1/2
30
Tel HaShomer
2026-03-01
Recruiting
Mahzi Therapeutics
Phase 1/2
12
Tel HaShomer
2025-12-19
Recruiting
Syndax Pharmaceuticals
Phase 3
468
Petah Tikva, Jerusalem, Tel Aviv, Tel HaShomer, Haifa
2025-11-25
Recruiting
Bayer
Phase 3
111
Haifa, Holon, Jerusalem, Tel Aviv, Tel HaShomer
2025-11-19
Recruiting
MRI-Guided Neoadjuvant Treatment De-Escalation in Stage II-III TNBC
NCT07327021TNBC, Triple Negative Breast Cancer, Early Breast Cancer
Tel-Aviv Sourasky Medical Center
Phase 2
54
Tel Aviv, Tel HaShomer
2025-11-11
Recruiting
A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP
NCT06920004Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, CIDP - Chronic Inflammatory Demyelinating Polyneuropathy
DrugsEmpasiprubart·IVIG
argenx
Phase 3
218
Ashkelon, Jerusalem, Tel HaShomer
2025-08-22
Active, closed
Safety and Performance, and Dose, of OsteoAdapt DE in Localized Alveolar Ridge Augmentations
NCT07078331Tooth Extraction Site Healing, Ridge Augmentation, Bone Graft
Theradaptive, Inc
Phase 1/2
45
Jerusalem, Petah Tikva, Tel Aviv, Tel HaShomer
2025-07-17
Active, closed
Arrowhead Pharmaceuticals
Phase 3
70
Jerusalem, Tel HaShomer
2025-06-17
Recruiting
Daiichi Sankyo
Phase 3
582
Haifa, Jerusalem, Kfar Saba, Petah Tikva, Tel Aviv, Tel HaShomer
2025-03-19
Recruiting
LUMENS-1 EU EFS CIP
NCT06761365Aneurysm Cerebral, Bifurcation, Unruptured Intracranial Aneurysm, Saccular Aneurysm
LuSeed Vascular LTD.
Not applicable
30
Tel HaShomer
2024-10-07
Recruiting
Hadassah Medical Organization
Not applicable
500
Afula, Beersheba, Jerusalem, Kfar Saba, Tel HaShomer
2024-09-30
Active, closed
Alpine Immune Sciences Inc, A Subsidiary of Vertex
Phase 3
605
Ashkelon, Petah Tivka, Tel HaShomer, Tsrifin
2024-08-30
Recruiting
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
NCT06419374Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
DrugPegozafermin
Hoffmann-La Roche
Phase 3
1,800
Afula, Beersheba, Haifa, Jerusalem, Nahariya, Petah Tikva, Tel Aviv, Tel HaShomer
2024-05-24
Recruiting
VE303 for Prevention of Recurrent Clostridioides Difficile Infection
NCT06237452Clostridium Difficile, Clostridium Difficile Infections, Clostridium Difficile Infection Recurrence, Clostridioides Difficile Infection
Vedanta Biosciences, Inc.
Phase 3
852
Petah Tikva, Tel Aviv, Tsrifin, Haifa, Hadera, Jerusalem, Ashkelon, Tel HaShomer
2024-05-20
Active, closed
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
NCT06372145Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
DrugTeriflunomide
Sanofi
Phase 3
2,500
Haifa, Rehovot, Safed, Tel HaShomer
2024-04-16
Recruiting
CSL Behring
Phase 3
35
Tel HaShomer
2024-01-30
Recruiting
Gilead Sciences
Phase 1
278
Haifa, Tel Aviv, Tel HaShomer
2024-01-09
Recruiting
Intellia Therapeutics
Phase 3
1,200
Haifa, Jerusalem, Tel HaShomer
2023-12-13
Recruiting
Regeneron Pharmaceuticals
Phase 3
904
Tel HaShomer, Ashdod, Haifa, Jerusalem, Nahariya, Tel Aviv
2023-12-13
Active, closed
Aura Biosciences
Phase 3
108
Tel-Hashomer
2023-12-06
Recruiting
Abbott Medical Devices
Observational
1,000
Tel HaShomer
2023-09-29
Active, closed
Sanofi
Phase 1/2
32
Tel HaShomer
2023-08-07
Active, closed
Praxis Precision Medicines
Phase 2/3
77
Tel HaShomer
2023-08-02
Active, closed
Bristol-Myers Squibb
Phase 3
579
Jerusalem, Afula, Petah-Tikvah, Tel Aviv, Tel HaShomer
2023-03-06
Active, closed
AstraZeneca
Observational
551
Kfar Saba, Tel Hashomer, Tiberias, Haifa, Jerusalem, Afula, Ramat Gan, Tel Aviv
2023-02-27
Active, closed
A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A
NCT05685238Haemophilia A, Haemophilia A With Inhibitors
Novo Nordisk A/S
Phase 3
451
Tel HaShomer
2023-02-13
Active, closed
Regeneron Pharmaceuticals
Phase 3
1,564
Afula, Jerusalem, Tel HaShomer
2023-01-16
Recruiting
Eli Lilly and Company
Phase 1
677
Petah Tikva, Tel HaShomer
2023-01-12
Recruiting
International Rare Brain Tumor Registry
NCT05697874Astroblastoma, BCOR ITD Sarcoma, CNS Sarcoma, Unclassified Tumor, Malignant
Children's National Research Institute
Observational
5,800
Haifa, Petah Tikva, Tel Aviv, Tel HaShomer
2023-01-01
Active, closed
AstraZeneca
Phase 3
368
Holon, Jerusalem, Petah Tikva, Tel Aviv, Tel HaShomer
2022-11-10
Active, closed
Vertex Pharmaceuticals Incorporated
Phase 3
822
Jerusalem, Petach Tikvah, Tel HaShomer
2022-11-08
Active, closed
Janssen Research & Development, LLC
Phase 2
577
Afula, Haifa, Jerusalem, Petah Tikva, Rehovot, Tel Aviv, Tel HaShomer, Tzrifin
2022-09-19
Active, closed
Novo Nordisk A/S
Phase 3
412
Beersheba, Haifa, Petah Tikva, Tel HaShomer, Tsrifin
2022-08-10
Active, closed
Janssen Research & Development, LLC
Phase 2
703
Afula, Haifa, Jerusalem, Petah Tikva, Rehovot, Tel Aviv, Tel HaShomer, Tzrifin
2022-07-22
Active, closed
Celgene
Phase 3
939
Afula, Haifa, Jerusalem, Tel Aviv, Tel HaShomer
2022-06-23
Recruiting
Priothera SAS
Phase 3
366
Haifa, Jerusalem, Tel Aviv, Tel HaShomer
2022-06-16
Active, closed
IO Biotech
Phase 3
407
Afula, Beersheba, Jerusalem, Petah Tikva, Tel Aviv, Tel HaShomer
2022-05-17
Recruiting
Combination Therapy for the Treatment of Diffuse Midline Gliomas
NCT05009992Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Recurrent Diffuse Intrinsic Pontine Glioma, Recurrent Diffuse Midline Glioma, H3 K27M-Mutant
DrugsDNX-2401·Dordaviprone·Paxalisib
University of California, San Francisco
Phase 2
360
Tel HaShomer, Jerusalem
2021-10-20
Active, closed
AstraZeneca
Phase 3
98
Beersheba, Jerusalem, Kfar Saba, Tel Aviv, Tel HaShomer
2021-09-12
Active, closed
VectivBio AG
Phase 3
158
Haifa, Tel HaShomer
2021-07-13
Active, closed
Boehringer Ingelheim
Phase 1
554
Haifa, Kfar Saba, Tel Aviv, Tel HaShomer
2021-07-02
Active, closed
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
NCT04637763Lymphoma, Non-Hodgkin, Relapsed Non Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Non Hodgkin Lymphoma
DrugsFludarabine·Cyclophosphamide
Caribou Biosciences, Inc.
Phase 1
72
Tel Aviv, Jerusalem, Petah Tikva, Tel HaShomer
2021-05-26
Active, closed
Incyte Corporation
Phase 3
654
Afula, Bear Sheva, BEER Yaaqov, Holon, Jerusalem, Kfar Saba, Petah Tikva, Tel HaShomer
2021-04-15
Recruiting
AstraZeneca
Phase 1
304
Kfar Saba, Tel HaShomer
2021-03-09
Active, closed
Hoffmann-La Roche
Phase 3
55
Tel HaShomer
2021-02-04
Active, closed
Amgen
Phase 3
135
Kfar Saba, Petah Tikva, Tel Aviv, Tel HaShomer
2020-12-04
Active, closed
Alexion Pharmaceuticals, Inc.
Phase 3
281
Haifa, Jerusalem, Petah Tikva, Tel Aviv, Tel HaShomer
2020-11-03
Recruiting
University of Birmingham
Phase 1/2
1,672
Haifa, Jerusalem, Petah Tikva, Tel Aviv, Tel HaShomer
2020-09-17
Active, closed
Alexion Pharmaceuticals, Inc.
Phase 3
125
Haifa, Jerusalem, Tel HaShomer
2020-08-25
Active, closed
Incyte Corporation
Phase 2
112
Jerusalem, Petah Tikva, Tel HaShomer
2020-08-03
Active, closed
Actelion
Phase 3
935
Haifa, Jerusalem, Rehovot, Tel HaShomer, Tsrifin
2020-06-30
Active, closed
Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia Without Inhibitors
NCT04082429Haemophilia A Without Inhibitors, Haemophilia B Without Inhibitors
DrugConcizumab
Novo Nordisk A/S
Phase 3
156
Tel HaShomer
2019-11-13
Active, closed
Novo Nordisk A/S
Phase 3
1,500
Haifa, Jerusalem, Kfar Saba, Petah Tikva, Tel Aviv, Tel HaShomer
2019-05-08
Recruiting
Assaf-Harofeh Medical Center
Phase 2
200
Afula, Haifa, Petah Tikva, Tel Aviv, Tel HaShomer, Tsrifin
2019-02-28
Active, closed
Acerta Pharma BV
Phase 3
984
Haifa, Jerusalem, Petah Tikva, Tel Aviv, Tel HaShomer
2019-02-25
Recruiting
Celgene
Phase 2/3
1,541
Beersheba, Jerusalem, Tel Aviv, Tel HaShomer
2018-07-19
Recruiting
Sheba Medical Center
Observational
20
Tel HaShomer
2018-07-01
Recruiting
Regeneron Pharmaceuticals
Phase 1/2
890
Haifa, Jerusalem, Tel HaShomer
2018-05-21
Active, closed
Biotronik SE & Co. KG
Observational
3,030
Ashdod, Beersheba, Holon, Jerusalem, Kfar Saba, Petah Tikva, Rehovot, Tel HaShomer
2018-05-14
Active, closed
Janssen Research & Development, LLC
Phase 3
629
Haifa, Jerusalem, Kfar Saba, Petach Tikvah, Tel Aviv, Tel HaShomer, Tzrifin
2018-03-23
Recruiting
Sheba Medical Center
Not applicable
100
Tel HaShomer
2017-11-03
Recruiting
A Study of Blood Based Biomarkers for Pancreas Adenocarcinoma
NCT03334708Pancreatic Cancer, Pancreatic Diseases, Pancreatitis, Pancreatic Cyst
Memorial Sloan Kettering Cancer Center
Observational
120
Jerusalem, Rehovot, Tel HaShomer
2017-10-30
Active, closed
NRG Oncology
Phase 2
218
Tel HaShomer
2017-04-07
Recruiting
The Natural History of Familial Dysautonomia
NCT03920774Familial Dysautonomia (Riley-Day Syndrome), Hereditary Sensory and Autonomic Neuropathies, Hereditary Sensory and Autonomic Neuropathy 3
NYU Langone Health
Observational
400
Tel HaShomer
2017-02-22
Active, closed
Celgene
Phase 1/2
466
Jerusalem, Tel Aviv, Tel HaShomer
2016-10-14
Active, closed
Geron Corporation
Phase 2/3
289
H̱olon, Kfar Saba, Rehovot, Jerusalem, Afula, Tel Aviv, Tel HaShomer, Haifa
2016-01-12
Active, closed
Acerta Pharma BV
Phase 3
533
Haifa, Jerusalem, Nahariya, Petah Tikvah, Tel HaShomer, Tiberias
2015-07-28
Active, closed
ETOP IBCSG Partners Foundation
Not applicable
518
Jerusalem, Tel HaShomer
2014-12-04
Active, closed
Karyopharm Therapeutics Inc
Phase 2
244
Beersheba, Haifa, Holon, Jerusalem, Petah Tikva, Tel Aviv, Tel HaShomer
2014-11
Active, closed
Eli Lilly and Company
Phase 3
453
Beersheba, Holon, Jerusalem, Kfar Saba, Petah Tikva, Tel HaShomer
2014-10-03
Recruiting
Boston Scientific Corporation
Observational
1,500
Jerusalem, Tel Aviv, Tel HaShomer
2014-03-04
Recruiting
Evaluation of Objective Perimetry Using Chromatic Multifocal Pupillometer
NCT02014389Retinal Dystrophies, Retinitis Pigmentosa, Glaucoma
Sheba Medical Center
Observational
200
Tel HaShomer
2013-12-01
Active, closed
Memorial Sloan Kettering Cancer Center
Observational
600
Jerusalem, Rehovot, Tel HaShomer
2013-11-04
Active, closed
AstraZeneca
Phase 3
510
Beersheba, Haifa, Kfar Saba, Petah Tikva, Tel Aviv, Tel HaShomer
2013-09-25
Active, closed
Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.
NCT01844986Newly Diagnosed, Advanced Ovarian Cancer, FIGO Stage III-IV, BRCA Mutation
DrugOlaparib
AstraZeneca
Phase 3
450
Haifa, Kfar Saba, Petah Tikva, Tel Aviv, Tel HaShomer
2013-08-26
Active, closed
NSABP Foundation Inc
Not applicable
1,636
Tel HaShomer
2013-08
Active, closed
Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
NCT01585805Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
DrugsVeliparib·Cis-platinum·CDDP·Gemcitabine
National Cancer Institute (NCI)
Phase 2
83
Jerusalem, Tel HaShomer
2012-05-15
Active, closed
Radiation Therapy Oncology Group
Phase 3
2,590
Petah Tikva, Tel HaShomer
2011-07
Active, closed
Radiation Therapy Oncology Group
Phase 3
2,354
Petah Tikva, Tel HaShomer
2011-05-24
Rows per page Showing 1–83 of 83
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Israeli investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 28 October 2026. https://priyalifescience.com/clinical-trials-israel/city/tel-hashomer

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Israel and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,438 studies in total at the last sync on 28 Oct 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 83 of those studies with a site in Tel HaShomer.

How many clinical trials are recruiting in Tel HaShomer?

33 of the 83 studies on this page are recruiting new participants as of the 28 Oct 2026, 03:18 UTC sync. A further 1 have not yet opened recruitment, 48 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Tel HaShomer), 83 studies
PhaseStudiesRecruitingShare
Phase 3421250.6%
Observational11813.3%
Phase 29310.8%
Phase 1/2839.6%
Not applicable536%
Phase 1536%
Phase 2/3313.6%

Most active sponsors

Lead sponsors with the most studies (Tel HaShomer)
Lead sponsorStudiesRecruiting
AstraZeneca61
Sheba Medical Center64
Novo Nordisk A/S40
Celgene31
Janssen Research & Development, LLC30
Regeneron Pharmaceuticals32
Acerta Pharma BV20
Alexion Pharmaceuticals, Inc.20
Bayer22
Eli Lilly and Company21
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.